Chapter 3. Cyclooxygenase Inhibitors

  1. Stephen D. Wiviott MD Assistant Professor Investigator
  1. Nina Chetty Raju MBBS, FRACP, FRCPA Clinical Research Fellow1 and
  2. John W. Eikelboom MBBS, MSc, FRACP, FRCPA Associate Professor2

Published Online: 19 FEB 2009

DOI: 10.1002/9781444303339.ch3

Antiplatelet Therapy In Ischemic Heart Disease

Antiplatelet Therapy In Ischemic Heart Disease

How to Cite

Chetty Raju, N. and Eikelboom, J. W. (2008) Cyclooxygenase Inhibitors, in Antiplatelet Therapy In Ischemic Heart Disease (ed S. D. Wiviott), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781444303339.ch3

Editor Information

  1. Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, TIMI Study Group, Boston, MA, USA

Author Information

  1. 1

    Thrombosis Service, Hamilton General Hospital, Department of Medicine McMaster University, Ontario, Canada

  2. 2

    Thrombosis Service, Hamilton General Hospital, Population Health Research Institute, Department of Medicine, McMaster University, Ontario, Canada

Publication History

  1. Published Online: 19 FEB 2009
  2. Published Print: 28 NOV 2008

Book Series:

  1. The AHA Clinical Series

Book Series Editors:

  1. Elliott Antman MD, FAHA

Series Editor Information

  1. Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, TIMI Study Group, Boston, MA, USA

ISBN Information

Print ISBN: 9781405176262

Online ISBN: 9781444303339

SEARCH

Keywords:

  • cyclooxygenase (COX) inhibitor;
  • COX physiology;
  • COX key role in arachidonic acid (AA) metabolism;
  • arachidonic acid cascade;
  • pharmacodynamics;
  • adverse effects of non-selective NSAIDs;
  • COX-inhibiting nitric oxide donors (CINODs)

Summary

This chapter contains sections titled:

  • Introduction

  • Historical development of COX inhibitors

  • COX physiology

  • COX inhibitors

  • Conclusion

  • References